🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to scientists.

An International Public Health Issue

Gonorrhoea infections are on the rise globally, with data suggesting more than 82 million infections each year. Particularly high rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This approval represents a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Research Study Data and Global Access

According to results detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This establishes an comparable level with the typical regimen, which combines an injection and a pill. The research involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Doctors directly involved have expressed positive views. Having a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered essential to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.